The U.S. Food and Drug Administration has authorized the first flu vaccine using messenger RNA technology developed by Moderna. Called mFLUSIVA, this new serum will be available to adults aged 50 and older in the United States.
The laboratory plans to market it as early as the 2026-2027 respiratory virus season. This approval comes after several months of uncertainty: in February, federal authorities initially refused to review the application, deeming the submitted clinical trials insufficient. The FDA ultimately agreed to resume the process after a meeting with Moderna.
Authorization obtained in a tense political climate
The green light comes as the Trump administration displays increasing distrust of mRNA vaccines. Donald Trump He had, however, presented this technology as a "modern-day miracle" during his first term, after its widespread use against Covid-19. His Secretary of Health, Robert F. Kennedy Jr., has since reduced some federal funding allocated to this research.
Moderna is thus seeking to expand the use of a technology that, along with Pfizer-BioNTech, enabled it to become one of the leading suppliers of Covid-19 vaccines. This first authorization in the field of influenza could open a new market for the company, even though political debates on vaccine approval procedures remain particularly heated in the United States.
Community
Comments
Write a comment
Be the first to comment on this article.